908 DEVICES INC. (MASS) Spending and interest coverage
- R&D / revenue · 12 months: Value 23.69%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 16.20%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 23.69% | Research and development expense / revenue. Period ending 2026-06-30. $14.41M ÷ $60.84M × 100 ≈ 23.69% |
| Stock-based compensation / revenue · 12 months | 16.20% | Share-based compensation / revenue. Period ending 2026-06-30. $9.86M ÷ $60.84M × 100 ≈ 16.20% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 14.41M USD | Research and Development Expense |
| Revenue | 60.84M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.86M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -38.93M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.41M | $60.84M | $9.86M | $-38.93M | (m) | 23.69% | 16.20% | (m) | (m) |
| 2026-03-31 | $15.22M | $57.80M | $9.88M | $-41.28M | (m) | 26.33% | 17.09% | (m) | (m) |
| 2025-12-31 | $15.57M | $56.20M | $9.85M | $-39.42M | (m) | 27.72% | 17.52% | (m) | (m) |
| 2025-09-30 | $26.48M | $65.05M | $9.90M | $-78.59M | (m) | 40.71% | 15.23% | (m) | (m) |
| 2025-06-30 | $26.85M | $65.56M | $10.72M | $-86.75M | (m) | 40.95% | 16.36% | (m) | (m) |
| 2025-03-31 | $26.03M | $63.99M | $11.48M | $-80.13M | (m) | 40.68% | 17.95% | (m) | (m) |
| 2024-12-31 | $25.50M | $59.63M | $11.76M | $-76.72M | (m) | 42.75% | 19.73% | (m) | (m) |
| 2024-09-30 | $24.40M | $55.16M | $11.28M | $-66.18M | (m) | 44.24% | 20.44% | (m) | (m) |
| 2024-06-30 | $23.15M | $52.69M | $10.78M | $-45.05M | (m) | 43.94% | 20.46% | (m) | (m) |
| 2024-03-31 | $22.30M | $50.73M | $10.26M | $-42.43M | (m) | 43.95% | 20.23% | (m) | (m) |
| 2023-12-31 | $21.90M | $50.23M | $9.79M | $-42.76M | $201.00K | 43.61% | 19.48% | -212.73× | Reported |
| 2023-09-30 | $21.12M | $47.52M | $9.45M | $-43.38M | $262.00K | 44.45% | 19.89% | -165.58× | Reported |
| 2023-06-30 | $20.25M | $49.02M | $8.77M | $-41.45M | $645.00K | 41.31% | 17.89% | -64.26× | Reported |
| 2023-03-31 | $19.02M | $48.03M | $8.08M | $-38.88M | $660.00K | 39.60% | 16.83% | -58.91× | Reported |
| 2022-12-31 | $17.53M | $46.85M | $7.21M | $-35.38M | $129.00K | 37.41% | 15.38% | -274.28× | Reported |
| 2022-09-30 | $16.61M | $51.05M | $6.08M | $-28.57M | $108.00K | 32.53% | 11.90% | -264.56× | Reported |
| 2022-06-30 | $15.24M | $47.80M | $4.87M | $-26.69M | $106.00K | 31.89% | 10.18% | -251.83× | Reported |
| 2022-03-31 | $14.01M | $44.97M | $3.45M | $-25.78M | $130.00K | 31.15% | 7.68% | -198.31× | Reported |
| 2021-12-31 | $13.07M | $42.21M | $2.50M | $-22.07M | $486.00K | 30.96% | 5.93% | -45.41× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.23M | $26.89M | $525.00K | $-5.82M | $976.00K | 30.62% | 1.95% | -5.96× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |